Lexicon Pharmaceuticals market cap LXRX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $640.7M
- Highest close in our data
- $2B
- Oct 2016
Lexicon Pharmaceuticals is worth $640.7M at the close on Nov 2, 2026, at $1.44 a share.
That is up 41% over the last year and down 8% over five years.
Its highest close in our data was $2B in Oct 2016.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $640.7M | $414.3M | $1.1B | +43% |
| 2025 | $447M | $131.3M | $541.5M | +60% |
| 2024 | $279.6M | $254.9M | $778.9M | −25% |
| 2023 | $374.7M | $247.4M | $658.7M | +4% |
| 2022 | $360.5M | $218.4M | $582.1M | −39% |
| 2021 | $586.6M | $451.1M | $999.7M | +46% |
| 2020 | $401.8M | $118.9M | $429.3M | −11% |
| 2019 | $452.7M | $127.5M | $798.7M | −32% |
| 2018 | $666.3M | $666.3M | $1.4B | −36% |
| 2017 | $1B | $1B | $1.9B | −27% |
| 2016 | $1.4B | $904.6M | $2B | +4% |
| 2015 | $1.4B | $458.2M | $1.5B | +194% |
| 2014 | $468.5M | $437.6M | $1B | −50% |
| 2013 | $934.6M | $903.8M | $1.5B | −4% |
| 2012 | $978.6M | $405.2M | $1.4B | +125% |
| 2011 | $435.6M | $310.7M | $459.2M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Lexicon Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| LXRXLexicon Pharmaceuticals | $640.7M |
| ZVRAZevra Therapeutics | $599.8M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| COLLCollegium Pharmaceutical | $770.9M |
| PBYIPuma Biotechnology | $525.5M |
| ABUSArbutus Biopharma | $791.4M |
| ARVNArvinas | $491.7M |
| CRMDCorMedix | $420.1M |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| OMEROmeros | $1.3B |
| ANABAnaptysbio | $1.4B |
| Peer median | $685.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Lexicon Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.